New logo expresses strengthened commitment to greater innovation, growth, and alignment with Saudi Vision 2030 ...

Management projected strong growth for 2025, driven by expanded reimbursement in key European markets such as Spain and Italy and the expected completion of the post-approval efficacy study (PAES).

Hansa Biopharma AB (HNSBF) reports a robust 35% increase in IDEFIRIX sales and expands its European market presence, despite facing revenue fluctuations and operating losses.

Q3 2025 Earnings Call Transcript February 4, 2025 Operator: Ladies and gentlemen, thank you for standing by. My name is ...

Q4 2024 Earnings Call Transcript February 4, 2025 Gartner, Inc. beats earnings expectations. Reported EPS is $5.45, ...

Hansa Biopharma AB, Hansa or the Company (Nasdaq Stockholm: HNSA) today announced its full year and Q4 2024 financial results. Søren ...

India has exported fresh produce such as baby corn and pomegranates to 17 new markets, such as Brazil, Georgia, Uganda, and ...

Q3 2025 Earnings Conference Call February 4, 2025 5:00 PM ETCompany ParticipantsRoger Sachs - Vice President and Head ...

Despite a dip in revenue, DXC Technology Co (DXC) showcases robust cash flow and strategic advancements in its Q3 2025 earnings call.

One worker died and four others were seriously injured when a workers’ bus, which had gone for a picnic from the Waluj ...

Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, has announced a collaboration with ...